Wednesday, July 8, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Patents matching “Alnylam Pharmaceuticals, Inc.”

376 pharma patents match "Alnylam Pharmaceuticals, Inc." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 376
Index total 30,257
Page 6 / 16

Quick answer

This filtered view shows 376 pharmaceutical patents matching "Alnylam Pharmaceuticals, Inc." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

376 results for “Alnylam Pharmaceuticals, Inc.” · 30,257 patents in full index Clear search

  1. US 10745704

    Compositions and methods for inhibiting expression of CD274/PD-L1 gene

    Alnylam Pharmaceuticals, Inc. · Granted Aug 18, 2020 · Expires Aug 13, 2040

    granted

  2. US 10745702

    Compositions and methods for inhibiting expression of the LECT2 gene

    Alnylam Pharmaceuticals, Inc. · Granted Aug 18, 2020 · Expires Aug 13, 2040

    granted

  3. US 10709728

    Polynucleotide agents targeting angiotensinogen (AGT) and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted Jul 14, 2020 · Expires Jul 9, 2040

    granted

  4. US 10683501

    Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases

    Alnylam Pharmaceuticals, Inc. · Granted Jun 16, 2020 · Expires Jun 11, 2040

    granted

  5. US 10683504

    Serpina1 iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted Jun 16, 2020 · Expires Jun 11, 2040

    granted

  6. US 10676740

    Modified iRNA agents

    Alnylam Pharmaceuticals, Inc. · Granted Jun 9, 2020 · Expires Jun 4, 2040

    granted

  7. US 10668170

    Modified RNAi agents

    Alnylam Pharmaceuticals, Inc. · Granted Jun 2, 2020 · Expires May 28, 2040

    granted

  8. US 10669303

    Compositions and methods directed to treating liver fibrosis

    Alnylam Pharmaceuticals, Inc. · Granted Jun 2, 2020 · Expires May 28, 2040

    granted

  9. US 10669544

    Therapeutic compositions

    Alnylam Pharmaceuticals, Inc. · Granted Jun 2, 2020 · Expires May 28, 2040

    granted

  10. US 10640770

    Hepatitis D virus (HDV) iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted May 5, 2020 · Expires Apr 30, 2040

    granted

  11. US 10612024

    Modified double-stranded RNA agents

    Alnylam Pharmaceuticals, Inc. · Granted Apr 7, 2020 · Expires Apr 2, 2040

    granted

  12. US 10612027

    Modified double-stranded RNA agents

    Alnylam Pharmaceuticals, Inc. · Granted Apr 7, 2020 · Expires Apr 2, 2040

    granted

  13. US 10597661

    Polynucleotide agents targeting patatin-like phospholipase domain containing 3 (PNPLA3) and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted Mar 24, 2020 · Expires Mar 19, 2040

    granted

  14. US 10570391

    RNAi agents, compositions and methods of use thereof for treating transthyretin (TTR) associated diseases

    Alnylam Pharmaceuticals, Inc. · Granted Feb 25, 2020 · Expires Feb 20, 2040

    granted

  15. US 10570393

    Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted Feb 25, 2020 · Expires Feb 20, 2040

    granted

  16. US 10557139

    Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted Feb 11, 2020 · Expires Feb 6, 2040

    granted

  17. US 10550386

    Monomers and oligonucleotides comprising cycloaddition adduct(s)

    Alnylam Pharmaceuticals, Inc. · Granted Feb 4, 2020 · Expires Jan 30, 2040

    granted

  18. US 10550390

    Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted Feb 4, 2020 · Expires Jan 30, 2040

    granted

  19. US 10513703

    Hepatitis B virus (HBV) iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted Dec 24, 2019 · Expires Dec 19, 2039

    granted

  20. US 10501742

    Compositions and methods for inhibiting expression of the PCSK9 gene

    Alnylam Pharmaceuticals, Inc. · Granted Dec 10, 2019 · Expires Dec 5, 2039

    granted

  21. US 10501740

    Compositions and methods for inhibiting expression of factor V

    Alnylam Pharmaceuticals, Inc. · Granted Dec 10, 2019 · Expires Dec 5, 2039

    granted

  22. US 10494632

    Insulin-like growth factor binding protein, acid labile subunit (IGFALS) compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted Dec 3, 2019 · Expires Nov 28, 2039

    granted

  23. US 10478500

    Compositions and methods for inhibition of HAO1 (Hydroxyacid Oxidase 1 (Glycolate Oxidase)) gene expression

    Alnylam Pharmaceuticals, Inc. · Granted Nov 19, 2019 · Expires Nov 14, 2039

    granted

  24. US 10472628

    Lipid formulated compositions and methods for inhibiting expression of Serum Amyloid A gene

    Alnylam Pharmaceuticals, Inc. · Granted Nov 12, 2019 · Expires Nov 7, 2039

    granted

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.